BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26039665)

  • 1. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
    Hall PE; Spicer J; Popat S
    Future Oncol; 2015; 11(15):2175-91. PubMed ID: 26039665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
    Rose M; Maurer A; Wirtz J; Bleilevens A; Waldmann T; Wenz M; Eyll M; Geelvink M; Gereitzig M; Rüchel N; Denecke B; Eltze E; Herrmann E; Toma M; Horst D; Grimm T; Denzinger S; Ecke T; Vögeli TA; Knuechel R; Maurer J; Gaisa NT
    Oncogene; 2020 Oct; 39(44):6856-6870. PubMed ID: 32978523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
    J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
    Jian H; Han Y; Yu Y; Lu S
    Anticancer Drugs; 2019 Sep; 30(8):873-878. PubMed ID: 31283542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
    Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
    Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
    Tagliamento M; Genova C; Rijavec E; Rossi G; Biello F; Dal Bello MG; Alama A; Coco S; Boccardo S; Grossi F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2055-2062. PubMed ID: 30392436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
    Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
    Sárosi V; Balikó Z
    Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of older patients with advanced non-small cell lung cancer: A challenge.
    Decoster L; Schallier D
    J Geriatr Oncol; 2019 Jul; 10(4):528-533. PubMed ID: 30301660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
    Álvarez-Fernández C; Esteban-González E
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():2-6. PubMed ID: 27426241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 19. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.